Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.

The Journal of clinical investigation - 1 Jun 2023

Zheng Liang, Zhu Zi-Ran, Sneh Tal, Zhang Wei-Tuo, Wang Zao-Yu, Wu Guang-Yu, He Wei, Qi Hong-Gang, Wang Hang, Wu Xiao-Yu, Fernández-García Jonatan, Abramovich Ifat, Xu Yun-Ze, Zhang Jin, Gottlieb Eyal

Abstract excerpt

Germline or somatic loss-of-function mutations of fumarate hydratase (FH) predispose patients to an aggressive form of renal cell carcinoma (RCC). Since other than tumor resection there is no effective therapy for metastatic FH-deficient RCC, an accurate method for early diagnosis is needed. Although MRI or CT scans are offered, they cannot differentiate FH-deficient tumors from other RCCs. Therefore, finding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Fumarate Hydratase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Neoplasms

Share to Mutation

Share to Succinic Acid

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37053010
DOI: 10.1172/JCI165028
PMCID: PMC10232000

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.PMID 37053010Read ↗

Genomic and Metabolic Hallmarks of SDH- and FH-Deficient Renal Cell CarcinomasSemantic proximity Read ↗

Fumarate hydratase-deficient renal cell carcinoma: a single institution-based study of 29 patients by clinicopathological, immunohistochemical and genetic approachesSemantic proximity Read ↗

Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.Semantic proximity Read ↗

Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell CarcinomasSemantic proximity Read ↗

AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell CarcinomaSemantic proximity Read ↗

Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinomaSemantic proximity Read ↗

Tislelizumab plus lenvatinib as the first-line therapy in patients with advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, single-centre, phase 2 trial and metabolic biomarker analysisSemantic proximity Read ↗

FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancerSemantic proximity Read ↗

Fumarate hydratase as a therapeutic target in renal cancerSemantic proximity Read ↗

Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.Semantic proximity Read ↗

Translating In Vivo Metabolomic Analysis of Succinate Dehydrogenase–Deficient Tumors Into Clinical UtilitySemantic proximity Read ↗

Metabolic Effects of Succinate Dehydrogenase Loss in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.